Navigation Links
Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
Date:2/5/2013

SAN DIEGO, Feb. 5, 2013 /PRNewswire/ -- Janssen Labs at San Diego, part of Janssen Research & Development, LLC (Janssen), today announced the addition of a Concept Lab and an Open Collaboration Space. The Concept Lab is a shared laboratory that offers entrepreneurs affordable access to single bench spaces to perform early-stage research before committing additional capital. The Open Collaboration Space is an open-plan office setting that provides companies and individuals with desk space in an environment that facilitates interactions with other life-science entrepreneurs. With these additions, Janssen Labs can now accommodate more than double the number of companies as when it opened.

(Logo: http://photos.prnewswire.com/prnh/20120117/LA36598LOGO)

These new offerings provide accessible, economical options for entrepreneurs to get to preclinical proof-of-concept by leveraging big company infrastructure, equipment and resources. Companies and individuals within the Concept Lab and the Open Collaboration Space will have access to the same amenities provided in the original Janssen Labs model, including more than 70 pieces of common equipment, as well as essential laboratory infrastructure, such as fume hoods, refrigeration, emergency power, emergency shower/eyewash, conference rooms and high-speed internet. The "no-strings-attached" model applies to all companies and individuals residing at Janssen Labs. 

"In the year since we opened, Janssen Labs has shown to be a place where emerging companies thrive. With the addition of the Concept Lab and Open Collaboration Space, we now can welcome additional scientists and tech entrepreneurs who will bring unique perspectives that can enrich our life science community," said Diego Miralles , M.D., head of Janssen West Coast Research Center.  "We are confident that the important work taking place within the labs and offices of this collaborative environment will serve patients worldwide by delivering novel solutions to significant unmet medical needs." 

The entrepreneurs utilizing the Concept Lab and the Open Collaboration Space can quickly begin their work in a capital-efficient manner and have the flexibility to move into a larger, private space at Janssen Labs when they require a larger footprint.  

Janssen Labs at a Glance
Janssen Labs currently has a total of 18 companies pursing novel technologies in the life sciences, including therapeutics, medical devices, diagnostics, tools and instrumentation.

  • 32,000-square foot life science innovation center
  • Modular Space: Modular wet lab units with access to specialized capital equipment and administrative areas
  • Concept Lab: Affordable shared laboratory with single bench spaces
    • Capacity to accommodate approximately 10 entrepreneurs
  • Open Collaboration Space: Open-plan office setting with desk space, cubicles, conference rooms
    • Capacity to accommodate at least 20 entrepreneurs
  • Growth & Progress
    • To date, one company has grown into a larger space within Janssen Labs and one company has already graduated to a larger, independent off-site facility. 
  • Applications: Currently accepting applications for all spaces. Visit www.janssenlabs.com.

About Janssen Labs at San Diego
Janssen Labs at San Diego, located at the Janssen Research & Development West Coast Research Center, is a life science innovation center providing emerging companies many of the advantages of being in a big company, without the capital investment. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at Janssen Labs also have access to core research labs hosting specialized capital equipment and shared administrative areas. Janssen Labs' operational support is provided by Prescience International, an external firm that specializes in the set-up and operations of life science innovation centers. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen.

Janssen Research & Development, LLC
Janssen Research & Development, LLC (Janssen), is one of the Janssen Pharmaceutical Companies. Janssen is headquartered in Raritan, N.J., and has facilities in Europe, the United States and Asia. Janssen is leveraging drug discovery and drug development in a variety of therapeutic areas, including Neuroscience, Oncology, Immunology, Infectious Diseases, and Cardiovascular and Metabolism to address unmet medical needs worldwide.  

More information can be found at www.janssenlabs.com


'/>"/>
SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
10. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
11. San Diego Based Neurosurgeon Offers Groundbreaking Treatment to Restore Function for People Suffering from Mobility Inhibiting Paralysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):